hydroxychloroquine has been researched along with Diabetes Mellitus in 36 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether taking hydroxychloroquine (HCQ) could prevent the development of new-onset diabetes mellitus (DM) among patients with Sjögren syndrome (SS)." | 7.91 | Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. ( Chen, TH; Chiou, JY; Hung, YM; Lai, TY; Wang, YH; Wei, JC, 2019) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 7.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 7.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "To determine the association between hydroxychloroquine use and the incidence of self-reported diabetes in a cohort of patients with rheumatoid arthritis." | 7.74 | Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. ( Elliott, JR; Fries, JF; Hubert, HB; Lingala, VB; Luggen, ME; Ward, MM; Wasko, MC, 2007) |
| " Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes." | 5.56 | Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "To determine whether taking hydroxychloroquine (HCQ) could prevent the development of new-onset diabetes mellitus (DM) among patients with Sjögren syndrome (SS)." | 3.91 | Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. ( Chen, TH; Chiou, JY; Hung, YM; Lai, TY; Wang, YH; Wei, JC, 2019) |
| " Univariate and multivariate analysis showed that higher numbers of system or organ involvement in SLE, abdominal obesity, hypertriglyceridemia and daily prednisolone of ≥ 1 mg/kg/day were the important associated factors of SDM (P ≤ 0." | 3.81 | Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. ( Gafor, AH; Kong, NC; Said, MS; Shaharir, SS, 2015) |
| "Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs." | 3.77 | Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. ( Canning, C; Garg, R; Liu, J; Massarotti, E; Schneeweiss, S; Solomon, DH, 2011) |
| "To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 3.76 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. ( Elliott, JR; Kao, AH; Kuller, L; Manzi, S; Penn, SK; Schott, LL; Toledo, FG; Wasko, MC, 2010) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 3.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "To determine the association between hydroxychloroquine use and the incidence of self-reported diabetes in a cohort of patients with rheumatoid arthritis." | 3.74 | Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. ( Elliott, JR; Fries, JF; Hubert, HB; Lingala, VB; Luggen, ME; Ward, MM; Wasko, MC, 2007) |
| " Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization." | 2.94 | A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. ( Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020) |
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| "This study aimed to analyze the effect of hydroxychloroquine combined with Huangqi tablets in the treatment of diabetic nephropathy (DN)." | 1.62 | The Efficacy of Hydroxychloroquine Combined with Huangqi Tablets in the Treatment of Diabetic Nephropathy. ( Chen, X; Kong, X; Sheng, D, 2021) |
| "Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action." | 1.62 | Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. ( Catrinoiu, D; Ceriello, A; Rizzo, M; Stoian, AP, 2021) |
| " Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes." | 1.56 | Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. ( Fu, X; Liu, Y; Xie, C, 2020) |
| "Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic." | 1.56 | Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. ( Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.56) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 10 (27.78) | 24.3611 |
| 2020's | 18 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Sheng, D | 1 |
| Kong, X | 1 |
| Dariya, B | 1 |
| Nagaraju, GP | 1 |
| Naymagon, L | 1 |
| Berwick, S | 1 |
| Kessler, A | 1 |
| Lancman, G | 1 |
| Gidwani, U | 1 |
| Troy, K | 1 |
| Xie, W | 1 |
| Yang, X | 1 |
| Ji, L | 1 |
| Zhang, Z | 1 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Stoian, AP | 1 |
| Catrinoiu, D | 1 |
| Rizzo, M | 1 |
| Ceriello, A | 1 |
| Davoudi-Monfared, E | 1 |
| Rahmani, H | 1 |
| Khalili, H | 1 |
| Hajiabdolbaghi, M | 1 |
| Salehi, M | 1 |
| Abbasian, L | 1 |
| Kazemzadeh, H | 1 |
| Yekaninejad, MS | 1 |
| Wang, Y | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Patel, M | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 1 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| Liu, Y | 1 |
| Fu, X | 1 |
| Xie, C | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Takeda, K | 1 |
| Sayer, G | 1 |
| Uriel, N | 1 |
| Naka, Y | 1 |
| Brusasco, C | 1 |
| Corradi, F | 1 |
| Di Domenico, A | 1 |
| Raggi, F | 1 |
| Timossi, G | 1 |
| Santori, G | 1 |
| Brusasco, V | 1 |
| Gao, C | 1 |
| Zhu, L | 1 |
| Jin, CC | 1 |
| Tong, YX | 1 |
| Xiao, AT | 1 |
| Zhang, S | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Lee, KH | 1 |
| Kim, JS | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Lee, S | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Dragioti, E | 1 |
| Li, H | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Petri, M | 2 |
| Magder, LS | 1 |
| Chen, TH | 1 |
| Lai, TY | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Hung, YM | 1 |
| Wei, JC | 1 |
| Shaharir, SS | 1 |
| Gafor, AH | 1 |
| Said, MS | 1 |
| Kong, NC | 1 |
| Uutela, T | 1 |
| Kautiainen, H | 1 |
| Järvenpää, S | 1 |
| Salomaa, S | 1 |
| Hakala, M | 1 |
| Häkkinen, A | 1 |
| Chen, YM | 1 |
| Lin, CH | 1 |
| Lan, TH | 1 |
| Chen, HH | 1 |
| Chang, SN | 1 |
| Chen, YH | 1 |
| Wang, JS | 1 |
| Hung, WT | 1 |
| Lan, JL | 1 |
| Chen, DY | 1 |
| Apostolopoulos, D | 1 |
| Morand, EF | 1 |
| Penn, SK | 1 |
| Kao, AH | 1 |
| Schott, LL | 1 |
| Elliott, JR | 2 |
| Toledo, FG | 1 |
| Kuller, L | 1 |
| Manzi, S | 1 |
| Wasko, MC | 2 |
| Rekedal, LR | 1 |
| Massarotti, E | 2 |
| Garg, R | 2 |
| Bhatia, R | 1 |
| Gleeson, T | 1 |
| Lu, B | 1 |
| Solomon, DH | 2 |
| Unübol, M | 1 |
| Ayhan, M | 1 |
| Guney, E | 1 |
| Liu, J | 1 |
| Canning, C | 1 |
| Schneeweiss, S | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Hubert, HB | 1 |
| Lingala, VB | 1 |
| Luggen, ME | 1 |
| Fries, JF | 1 |
| Ward, MM | 1 |
| Tanay, A | 1 |
| Leibovitz, E | 1 |
| Frayman, A | 1 |
| Zimlichman, R | 1 |
| Shargorodsky, M | 1 |
| Gavish, D | 1 |
| Di Comite, G | 1 |
| Rossi, CM | 1 |
| Wallace, DJ | 1 |
| Yonemura, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis[NCT01132118] | Phase 3 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [NCT00005436] | 0 participants | Observational | 1991-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 58.1 | 59.4 | 1.3 |
| Placebo | 58.1 | 60.3 | 2.2 |
HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mIU x dL)/(L x mg) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 116.5 | 110.8 | -5.8 |
| Placebo | 116.5 | 109.7 | -6.8 |
"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mg x mIU)/(dL*L) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 2.0 | 1.7 | -0.3 |
| Placebo | 2.0 | 1.6 | -0.42 |
"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (dL x L)/(mg x mIU) (Mean) | ||
|---|---|---|---|
| Baseline | Period Value | Change | |
| Hydroxychloroquine | 7.7 | 8.1 | 0.4 |
| Placebo | 7.7 | 7.8 | 0.14 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 114.1 | 101.7 | -12.4 |
| Placebo | 114.1 | 109.9 | -4.2 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 192.4 | 179.7 | -12.7 |
| Placebo | 192.4 | 189.4 | -3.0 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 100.6 | 92.4 | -8.2 |
| Placebo | 100.6 | 95.6 | -5.0 |
8 reviews available for hydroxychloroquine and Diabetes Mellitus
| Article | Year |
|---|---|
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbid | 2020 |
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Glucocorticoids; Humans; Hydroxychlo | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.
Topics: Antirheumatic Agents; Baltimore; Blood Glucose; Cohort Studies; Diabetes Complications; Diabetes Mel | 1996 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Tria | 1996 |
[Review of electroretinography: 1970].
Topics: Animals; Anura; Cats; Cyprinidae; Diabetes Mellitus; Dogs; Electrooculography; Electroretinography; | 1971 |
1 trial available for hydroxychloroquine and Diabetes Mellitus
| Article | Year |
|---|---|
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbi | 2020 |
27 other studies available for hydroxychloroquine and Diabetes Mellitus
| Article | Year |
|---|---|
The Efficacy of Hydroxychloroquine Combined with Huangqi Tablets in the Treatment of Diabetic Nephropathy.
Topics: Blood Glucose; Diabetes Mellitus; Diabetic Nephropathies; Humans; Hydroxychloroquine; Kidney; Tablet | 2021 |
The emergence of methemoglobinemia amidst the COVID-19 pandemic.
Topics: Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes M | 2020 |
Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
Topics: Blood Glucose; COVID-19; COVID-19 Drug Treatment; Diabetes Complications; Diabetes Mellitus; Glycemi | 2021 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Topics: Anti-Infective Agents; Betacoronavirus; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; | 2020 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.
Topics: Adult; Aged; Aged, 80 and over; Air Filters; Algorithms; Antibodies, Monoclonal, Humanized; Antirheu | 2021 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug | 2020 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome.
Topics: Adult; Aged; Antirheumatic Agents; Databases, Factual; Diabetes Mellitus; Female; Glucose; Humans; H | 2019 |
Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; China; Cohort Studies; Cross-Sectional Studies | 2015 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
Topics: Adolescent; Adult; Antirheumatic Agents; Cohort Studies; Diabetes Mellitus; Dose-Response Relationsh | 2015 |
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2010 |
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Diabetes Mellitus; Female; Glycate | 2010 |
Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Diabetes Mellitus; Female; Humans; | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Hum | 2007 |
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Hum | 2007 |
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Hum | 2007 |
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Hum | 2007 |
Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arteries; Diabetes Mellitus; Elasticity; Female; Huma | 2007 |
Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus; Glucocorticoids; Humans; Hydroxychlo | 2007 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |